Agilent has given its latest Thought Leader Award to Dr. Ronald DePinho, a world-renowned researcher and oncologist. The award will support his research into metabolic reprogramming in the earliest stages of pancreatic cancer. DePinho is president of the University of Texas MD Anderson Cancer Center, ranked as one of the world’s most respected cancer research and treatment centers.
DePinho and his team will work with scientists from the university’s newly formed Institute of Applied Cancer Sciences, utilizing state-of-the-art pancreatic cancer transgenic animal models, tumor cell lines and patient samples.
Commenting on the award, DePinho said, “I am extremely pleased to receive this award for metabolomics research, as the survival rates for pancreatic cancer have not significantly improved over the past 20 years.” He added that the technology will allow his team to identify new targets that drive the formation, progression and maintenance of pancreatic cancer.
The Agilent Thought Leader Award program promotes fundamental advances in the life sciences and chemical analysis by contributing financial support, products and expertise to the research of influential scientists.
For more information go to: